The news out of Abuja should make your blood boil. A woman travels from Uganda to Nigeria, falls violently ill on October 7, and spends four days languishing in a hospital ward before anyone confirms the nightmare: Ebola. She is fighting for her life in the capital of Africa’s most populous country, a bustling metropolis of millions. The international wire services will report this with the usual clinical detachment, describing a virus that simply wanders across borders like bad weather. Do not let them lie to you. This is not a tragedy of nature. It is the predictable, calculated fallout of a global medical cartel that measures the value of human life exclusively in quarterly earnings.
I keep thinking about the nurses who had to care for that woman during those four terrifying days before the diagnosis came down. I have spent years listening to healthcare workers on the sharp end of bureaucratic negligence—nurses in underfunded county hospitals in the Bronx and overworked clinic staff in rural clinics—and their fear is always the same. They are handed flimsy paper masks, plastic aprons that tear at the shoulder, and a pat on the head, while administrators run the spreadsheets. Now imagine being an orderly or an underpaid nurse in a public hospital in Abuja, cleaning up vomit and blood with basic latex gloves because the resources for real biosafety infrastructure were stripped away decades ago. The people who do the actual dirty, heroic work of medicine are always the first to be fed into the meat grinder.
Why are we still fighting Ebola outbreaks with containment cordons, tracing teams, and prayers in 2026? Because the pharmaceutical barons who own our healthcare system decided a long time ago that poor people in central and western Africa do not represent a lucrative enough customer base. The science to manufacture, stockpile, and rapidly deploy robust treatments and cross-strain vaccines has existed for years. Much of the underlying research was funded not by private risk-takers, but by public tax dollars handed over to university laboratories and government agencies.
Yet the moment a breakthrough occurs, corporate monopolists swoop in to patent the molecular biology, lock the formulas behind impenetrable intellectual property walls, and refuse to transfer manufacturing technology to facilities in the Global South. Executives like Albert Bourla at Pfizer and Stéphane Bancel at Moderna made historic fortunes turning public science into private windfalls during COVID-19, institutionalizing an apartheid model of distribution that left developing nations at the back of the line. The same predatory logic governs filoviruses. Monoclonal antibody treatments and specialized vaccines languish in tiny, high-priced stockpiles, rationed like gold bullion, because treating outbreaks in Uganda or the Democratic Republic of Congo will never yield the margins of a weight-loss drug or a daily hair-loss pill sold in Manhattan.
The villains do not just sit in boardroom towers in New York, Basel, and London; they also occupy the bureaucratic halls of the International Monetary Fund and the World Bank. For half a century, Western financial institutions forced developing nations to sign structural adjustment programs, demanding that governments gut their civil services, privatize utilities, and cut public health spending to the bone to service foreign debt. You cannot dismantle a continent’s public health foundation for fifty years and then express shock when a deadly virus slips undetected through a transportation hub. Abuja’s vulnerability was bought and paid for on Wall Street.
Right now, Western defense departments and health agencies are likely scrambling, not out of solidarity with Nigerian or Ugandan families, but out of raw, self-interested terror that the virus might board an international flight bound for London, Paris, or Atlanta. That is the only language our ruling class understands. When Ebola stays contained within the borders of poor, black nations, it is an academic footnote for the tropical disease journals. The moment it threatens European or American financial centers, suddenly billions of dollars in emergency military-industrial contracts materialize overnight.
The sick woman in Abuja is not a statistic, and the medical workers currently praying over their temperature logs are not collateral damage. They are victims of a system run by patent hoarders, private equity scavengers, and austerity-mongering technocrats who would rather watch an entire hemisphere burn than surrender an ounce of corporate monopoly power. We do not need more condescending sympathy from the international community. We need the immediate, unconditional waiver of all pharmaceutical patents, the forced transfer of vaccine manufacturing tech to regional hubs, and a Nuremberg-style reckoning for the pharmaceutical executives who made a fortune off artificial scarcity while ordinary people bled to death in the dark.